{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', '6.4.7.', 'Itch Numeric Rating Scale (NRS)', '36', '6.4.8.', 'Skin Discomfort/Pain Visual Analog Scale (VAS)', '36', '6.4.9.', 'Body Surface Area (BSA)', '36', '6.4.10.', 'Psoriasis Area Severity Index (PASI)', '36', '6.4.11.', 'Patient Benefit Index (PBI)', '37', '6.4.12.', 'The European Quality of Life 5-Dimension Questionnaire (EQ-5D)', '37', '6.4.13.', 'The Work Productivity and Activity Impairment Questionnaire: Psoriasis', '(WPAI: PSO)', '37', '37', '6.4.15.', 'Photography', '37', '6.5.', 'Safety Assessments', '38', '6.5.1.', 'Serum and Urine Pregnancy Tests for Females of Childbearing Potential', '38', '6.5.2.', 'Vital Signs, Weight and Waist Circumference', '38', '6.5.3.', 'Physical Examination', '38', '6.5.4.', 'Psychiatric Evaluation', '39', '6.5.5.', 'Severe Diarrhea, Nausea and Vomiting', '39', '6.5.6.', 'Clinical Laboratory Evaluations', '39', '6.5.7.', 'Tuberculosis', '39', '6.5.8.', 'Adverse Events', '40', '7.', 'DESCRIPTION OF STUDY TREATMENTS', '41', '7.1.', 'Description of Investigational Product(s)', '41', '7.2.', 'Treatment Administration and Schedule', '41', '7.3.', 'Method of Treatment Assignment', '41', '7.4.', 'Packaging and Labeling', '42', '7.5.', 'Investigational Product Accountability and Disposal', '42', '7.6.', 'Investigational Product Compliance', '42', '7.7.', 'Overdose', '43', '8.', 'CONCOMITANT MEDICATIONS AND PROCEDURES', '44', '8.1.', 'Permitted Concomitant Medications and Procedures', '44', '8.2.', 'Concomitant Medications Not Recommended', '44', '8.3.', 'Prohibited Concomitant Medications and Procedures', '44', '8.4.', 'Required Concomitant Medications and Procedures', '45', '9.', 'STATISTICAL CONSIDERATIONS', '46', 'Confidential and Proprietary', '11', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', '9.1.', 'Overview', '46', '9.2.', 'Study Population Definitions', '46', '9.3.', 'Sample Size and Power Considerations', '46', '9.4.', 'Background and Demographic Characteristics', '47', '9.5.', 'Subject Disposition', '47', '9.6.', 'Efficacy Analysis', '47', '9.6.1.', 'Primary Endpoint', '47', '9.6.2.', 'Secondary and Exploratory Efficacy Endpoints', '48', '9.6.3.', 'Photography', '48', '48', '9.6.5.', 'Multiplicity Adjustment', '49', '9.7.', 'Safety Analysis', '49', '9.8.', 'Interim Analysis', '49', '9.9.', 'Other Topics', '49', '9.9.1.', 'Investigational Product Compliance (Tablets)', '49', '9.9.2.', 'Concomitant Therapy', '50', '9.9.3.', 'Steering Committee', '50', '10.', 'ADVERSE EVENTS', '51', '10.1.', 'Monitoring, Recording and Reporting of Adverse Events', '51', '10.2.', 'Evaluation of Adverse Events', '51', '10.2.1.', 'Seriousness', '51', '10.2.2.', 'Severity / Intensity', '53', '10.2.3.', 'Causality', '53', '10.2.4.', 'Duration', '54', '10.2.5.', 'Action Taken', '54', '10.2.6.', 'Outcome', '54', '10.3.', 'Abnormal Laboratory Values', '54', '10.4.', 'Pregnancy', '55', '10.4.1.', 'Females of Childbearing Potential - Collection of Pregnancy Information', '55', '10.4.2.', 'Male Subject With Partners Who Become Pregnant', '56', '10.4.3.', 'Collection of Lactation Information', '56', '10.5.', 'Reporting of Serious Adverse Events', '56', '10.5.1.', 'Safety Queries', '57', 'Confidential and Proprietary', '12', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}